Danish vaccine maker Bavarian Nordic on Friday reported a 33% rise in first-half revenue, posting strong results as it prepares for a takeover by a private equity consortium.
The company, which in July agreed to a 19 billion Danish Krone buyout offer from firms including Nordic Capital and Permira, said revenue for the six months ended June 30 rose to nearly 3.0 billion Danish Krone from 2.3 billion a year earlier.
Growth was driven by a 24% increase in its Travel Health business and a 51% jump in its Public Preparedness division, which supplies governments with mpox and smallpox vaccines, according to the company.
Earnings before interest, taxes, depreciation, and amortization reached 961 million Danish Krone.
"We are pleased to report a strong first half of 2025, which fully captures our successful commercial transformation over the past years, in line with our growth strategy," Chief Executive Paul Chaplin said in a statement.
Bavarian Nordic refined its full-year guidance, narrowing its revenue forecast to between 6.0 billion and 6.6 billion Danish Krone.
The company also said it expects its total EBITDA margin to be between 40% and 42% for the full year, boosted by the recent sale of a Priority Review Voucher for $160 million.
The consortium's offer document is expected to be published by Aug. 26, the company said.
More from this issuer
Related coverage
Bavarian Nordic's Chair of the Board, Luc Debruyne, has resigned with immediate effect, the Danish vaccine maker said, days after a takeover bid from a private equity consortium collapsed.
Bavarian Nordic's Chair of the Board, Luc Debruyne, has resigned with immediate effect, the Danish vaccine maker announced Thursday, days after a private equity takeover bid for the company collapsed.
A takeover offer for Danish vaccine maker Bavarian Nordic from a private equity consortium led by Nordic Capital and Permira has been withdrawn after failing to gain sufficient shareholder support.
A private equity consortium's takeover bid for Danish vaccine maker Bavarian Nordic is facing a crucial deadline, complicated by a major new European vaccine contract that could bolster the company's standalone value.